Fusion of histone variants to Cas9 suppresses non-homologous end joining.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 29 06 2023
accepted: 11 01 2024
medline: 13 5 2024
pubmed: 13 5 2024
entrez: 13 5 2024
Statut: epublish

Résumé

As a versatile genome editing tool, the CRISPR-Cas9 system induces DNA double-strand breaks at targeted sites to activate mainly two DNA repair pathways: HDR which allows precise editing via recombination with a homologous template DNA, and NHEJ which connects two ends of the broken DNA, which is often accompanied by random insertions and deletions. Therefore, how to enhance HDR while suppressing NHEJ is a key to successful applications that require precise genome editing. Histones are small proteins with a lot of basic amino acids that generate electrostatic affinity to DNA. Since H2A.X is involved in DNA repair processes, we fused H2A.X to Cas9 and found that this fusion protein could improve the HDR/NHEJ ratio by suppressing NHEJ. As various post-translational modifications of H2A.X play roles in the regulation of DNA repair, we also fused H2A.X mimicry variants to replicate these post-translational modifications including phosphorylation, methylation, and acetylation. However, none of them were effective to improve the HDR/NHEJ ratio. We further fused other histone variants to Cas9 and found that H2A.1 suppressed NHEJ better than H2A.X. Thus, the fusion of histone variants to Cas9 is a promising option to enhance precise genome editing.

Identifiants

pubmed: 38739603
doi: 10.1371/journal.pone.0288578
pii: PONE-D-23-20236
doi:

Substances chimiques

Histones 0
CRISPR-Associated Protein 9 EC 3.1.-
Recombinant Fusion Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0288578

Informations de copyright

Copyright: © 2024 Kato-Inui et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Tomoko Kato-Inui (T)

Tokyo Metropolitan Institute of Medical Science, Regenerative Medicine Project, Tokyo, Japan.

Gou Takahashi (G)

Tokyo Metropolitan Institute of Medical Science, Regenerative Medicine Project, Tokyo, Japan.

Terumi Ono (T)

Tokyo Metropolitan Institute of Medical Science, Regenerative Medicine Project, Tokyo, Japan.
Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Yuichiro Miyaoka (Y)

Tokyo Metropolitan Institute of Medical Science, Regenerative Medicine Project, Tokyo, Japan.
Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
Graduate School of Humanities and Sciences, Ochanomizu University, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH